Company Information
USD
58.86
- (-1.6%)
NASDAQ:BMRN, BIOMARIN PHARMACEUTICAL INC.
Industry: Biotechnology
End of Day: 9 May 2025 GMT-4
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Address
770 Lindaro Street
Website
Classification
Sector
Healthcare
Industry Group
Biotechnology
Industry
Biotechnology
Key Executives
Mr. Jeffrey R. Ajer
Executive VP/Other Executive Officer
Dr. Elaine J. Heron,PhD
Director
Mr. Jean-Jacques Bienaime
Director
Mr. Richard A. Meier
Chairman of the Board/Director
Mr. David E.I. Pyott, M.B.A.,M.D.
Director
Dr. V. Bryan Lawlis, PhD
Director
Mr. Robert J. Hombach
Director
Mr. Brian R. Mueller
CFO/Executive VP
Mr. Mark J. Alles
Director
Dr. Athena Countouriotis, M.D.
Director
Mr. Mark Joseph Enyedy
Director
Dr. Dennis J. Slamon, M.D.,PhD
Director
Dr. Maykin Ho, PhD
Director
Ms. Barbara W. Bodem
Director
Ms. Elizabeth McKee Anderson, M.B.A.
Director
Ms. Erin Burkhart
Chief Accounting Officer/Vice President
Mr. Alexander Hardy
CEO/Director/President
Dr. Henry J. Fuchs,M.D.
President, Divisional
Dr. Willard H. Dere, M.D.
Director
Mr. G. Eric Davis
Chief Legal Officer/Executive VP/Secretary
Mr. Charles Greg Guyer
Chief Technology Officer/Executive VP
Ownership
Institution Holdings
PRIMECAP Management Company
18,414,374 (9.760%)
Vanguard Group Inc
18,050,062 (9.567%)
BlackRock Inc
14,681,644 (7.781%)
Dodge & Cox
13,994,063 (7.417%)
Capital Research Global Investors
10,774,641 (5.711%)
Capital Research and Management Company
10,751,505 (5.698%)
Capital Group
10,171,748 (5.391%)
State Street Corporation
6,730,515 (3.567%)
Vanguard Investments Australia Ltd
6,018,522 (3.190%)
Ameriprise Financial Inc
5,419,366 (2.872%)
Funds Holdings
Vanguard PrimeCap Fund
6,826,903 (3.618%)
Capital Group AMCAP Composite
5,954,810 (3.156%)
VA CollegeAmerica AMCAP Fd
5,954,810 (3.156%)
Vanguard Total Stock Market Index Fund
5,918,428 (3.137%)
Vanguard US Total Market Shares ETF
5,918,428 (3.137%)
Vanguard Capital Opportunity Fund
5,371,580 (2.847%)
Vanguard Mid-Cap Index Fund
4,220,399 (2.237%)
Vanguard Institutional Extnd Mkt Idx Tr
2,779,438 (1.473%)
PrimeCap Odyssey Aggressive Growth Fund
1,936,710 (1.026%)
Vanguard Growth Index Fund
1,736,457 (0.920%)
Make Smart Investment Choices
GoodWhale Pte. Ltd.
1557 Keppel Road, #01-01
Singapore 089066
Singapore 089066
